In this regard, we showed that significant metabolic alterations (hyperglycemia, dyslipidemia, and high rate of metabolic syndrome) observed in patients with PA were associated with increased expression of leptin and resistin in the visceral AT and consensual reduced expression of adiponectin, suggesting a relevant role of these adipokines in the development of metabolic changes observed in patients with PA (3). The gene discussed is LEP; the disease is metabolic syndrome.